Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative antiviral therapeutics targeting serious viral diseases, including hepatitis C, influenza, and norovirus infections. Utilizing advanced structure-based technologies, the company is developing CC-31244, a non-nucleoside polymerase inhibitor currently undergoing Phase 2a clinical trials for hepatitis C. Additionally, Cocrystal is advancing CC-42344, a PB2 inhibitor for influenza, which is in preclinical development. The company has established research collaborations, including an exclusive agreement with Merck Sharp & Dohme Corp. to develop proprietary antiviral agents for influenza A and B, as well as a license with Kansas State University Research Foundation to create antiviral treatments for norovirus and coronavirus infections. Headquartered in Bothell, Washington, Cocrystal Pharma continues to explore and develop promising antiviral compounds using its proprietary drug design technology.
RFS Pharma
Acquisition in 2014
RFS Pharma, LLC is a clinical-stage biopharmaceutical company founded by Dr. Raymond F. Schinazi, dedicated to developing innovative treatments for hepatitis infections and emerging viruses. Based in Tucker, Georgia, the company operates from a laboratory facility that focuses on biotechnological development and research capabilities, particularly in antiviral agents and nucleoside chemistry. Since its incorporation in 2004, RFS Pharma has made significant strides in the pharmaceutical sector, notably in-licensing anti-hepatitis technology from Emory University in 2013. The company is also actively exploring opportunities to in-license promising new drugs to expand its pipeline and contribute to advancements in the pharmaceutical industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.